Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Galectin Therapeutics Inc (NASDAQ: GALT).

Full DD Report for GALT

You must become a subscriber to view this report.


Recent News from (NASDAQ: GALT)

Your Daily Pharma Scoop: Galectin Phase 3 Trial, Acer NDA, Chiasma SPA Amendments
Analysis focus: GALT Galectic (GALT) was our focus ticker in one of the articles in the NASH series we did in February. There, we discussed what makes Galectin stand out among the NASH companies. First, it is not a one-trick pony and has a diverse pipeline outside NASH. Second, unlike Genf...
Source: SeekingAlpha
Date: May, 15 2018 10:00
Today's Research Reports on Stocks to Watch: Tandem Diabetes Care and Galectin Therapeutics
NEW YORK, NY / ACCESSWIRE / May 15, 2018 / Tandem shares saw an increase in their share price after an analyst at Piper Jaffray upped his price target to $13 from $8. Shares of Galectin Therapeutics also saw a rise after the company announced its plans to begin a Phase 3 clinical trial prog...
Source: ACCESSWIRE IA
Date: May, 15 2018 08:00
Midday Gainers / Losers (05/14/2018)
Gainers:  IMTE +59% . GALT +29% . EOLS +24% . BOXL +21% . AST +21% . TNDM +18% . CLWT +17% . FRED +17% . ASCMA +16% . MYO +16% . More news on: Integrated Media Technology Limited, Galectin Therapeutics, Inc., Evolus, Inc., Stocks on the move, , Read...
Source: SeekingAlpha
Date: May, 14 2018 12:46
Galectin to advance NASH candidate GR-MD-02 into Phase 3
Galectin Therapeutics (NASDAQ: GALT ) announces its plan to advance GR-MD-02 into Phase 3 development for the treatment of NASH cirrhosis. More news on: Galectin Therapeutics, Inc., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 14 2018 09:24
Galectin Therapeutics Proceeds to Phase 3 Development of GR-MD-02 for NASH Cirrhosis Following FDA Meeting
NORCROSS, Ga., May 14, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today it is proceeding with plans for a Phase 3 clinical trial program with its galectin-3 inhibitor GR-MD-02 in ...
Source: GlobeNewswire
Date: May, 14 2018 09:05
Galectin Therapeutics beats by $0.01
Galectin Therapeutics (NASDAQ: GALT ): Q1 EPS of -$0.12 beats by $0.01 . Cash and equivalents of $3.99M Press Release More news on: Galectin Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: May, 11 2018 16:13
Galectin Therapeutics Reports 2018 First Quarter Financial Results and Provides Business Update
NORCROSS, Ga., May 11, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for the three months ended March 31, 2018, and provided a business update. These results are includ...
Source: GlobeNewswire
Date: May, 11 2018 16:10
Cirius Therapeutics completes enrollment in mid-stage study of lead candidate in NASH
Privately held Cirius Therapeutics announces that it has reached the enrollment target in a Phase 2b clinical trial, EMMINENCE , assessing lead candidate MSDC-0602K in patients with NASH and liver fibrosis. More news on: Conatus Pharmaceuticals, Galectin Therapeutics, Inc., Navidea Bi...
Source: SeekingAlpha
Date: May, 02 2018 10:47
Recent Analysis Shows Alphabet, Northrop Grumman, HomeStreet, Galectin Therapeutics, AZZ, and Restoration Robotics Market Influences - Renewed Outlook, Key Drivers of Growth
NEW YORK, April 26, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Alphabet Inc. (NASDAQ:GOOGL), Northrop Grumman Corporation (NYSE:NOC), H...
Source: GlobeNewswire
Date: April, 26 2018 07:55
Blog Exposure - Adamas Pharma Announced Final Results from EASE LID 2 Study Evaluating GOCOVRI in Parkinson's Disease Patients with Dyskinesia
Stock Monitor: Galectin Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 23, 2018 / Active-Investors.com has just released a free research report on Adamas Pharma, Inc. (NASDAQ: ADMS ). If you want access to this report all you need to do is sign up now by clickin...
Source: ACCESSWIRE IA
Date: April, 23 2018 07:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-173.843.854.073.8187298,405
2018-08-163.733.863.883.55539,316
2018-08-153.893.664.173.5311,119,582
2018-08-144.104.04394.623.98785,389
2018-08-134.774.084.803.801,197,378

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1766,567146,89545.3160Short
2018-08-16103,222211,42848.8213Short
2018-08-15176,177372,12147.3440Short
2018-08-1460,126192,34331.2598Cover
2018-08-13254,349434,01658.6036Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on GALT.


About Galectin Therapeutics Inc (NASDAQ: GALT)

Logo for Galectin Therapeutics Inc (NASDAQ: GALT)

Galectin is a clinical development stage biopharmaceutical company based in Norcross, Georgia, that is targeting fibrotic diseases and cancer with novel galectin inhibitor compounds. Galectins are a class of proteins made by many cells in the body and are important therapeutic targets because they are the mediators of fundamental biologic mechanisms in pathological processes. Galectin Therapeutics leverages its extensive scientific knowledge of galectins to advance their discovery program including research and discovery of new compounds. Through a relationship with a world class research program at the University of Georgia, the Company focuses on the discovery of new carbohydrate molecules that can be used in the therapy of diseases where galectin proteins play a major role including cancer and inflammatory and fibrotic disorders.

 

 

 

Current Management

  • Peter G. Traber / CEO, President, CMO
  • Harold Shlevin / COO, Corporate Secretary
  • Jack Callicutt / CFO

Current Share Structure

  • Market Cap: $155,914,944 - 05/16/2018
  • Issue and Outstanding: 37,569,866 - 03/16/2018

 


Recent Filings from (NASDAQ: GALT)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 14 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 16 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 11 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: March, 30 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 29 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 29 2018
Annual statement of changes in beneficial ownership of securities
Filing Type: 5Filing Source: edgar
Filing Date: February, 07 2018
Annual statement of changes in beneficial ownership of securities
Filing Type: 5Filing Source: edgar
Filing Date: February, 07 2018

 

 


Daily Technical Chart for (NASDAQ: GALT)

Daily Technical Chart for (NASDAQ: GALT)


Stay tuned for daily updates and more on (NASDAQ: GALT)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: GALT)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in GALT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of GALT and does not buy, sell, or trade any shares of GALT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/